Federal Reclassification Order Drops Cannabis to Schedule III

Acting Attorney General Todd Blanche has signed the formal order reclassifying marijuana from Schedule I to Schedule III under the Controlled Substances Act, completing a regulatory process that began under the Biden administration. The reclassification applies specifically to state-licensed medical marijuana programs, representing the most significant federal policy shift on cannabis since the drug's initial prohibition.

The Schedule III designation places cannabis alongside drugs like ketamine and testosterone, acknowledging accepted medical uses while maintaining federal oversight. This contrasts sharply with Schedule I's classification alongside heroin and LSD, which assumes no medical value. The change enables state-licensed medical marijuana businesses to claim standard tax deductions under Section 280E, potentially improving margins across the industry.

Cannabis operators have faced crushing tax burdens under 280E restrictions, often paying effective rates exceeding 70% due to their inability to deduct ordinary business expenses. The reclassification removes this penalty for state-compliant medical programs, though recreational cannabis businesses may still face restrictions depending on implementation details from the Drug Enforcement Administration.

The order creates a two-tiered federal approach to cannabis regulation, distinguishing between medical and recreational use. Multi-state operators with significant medical market exposure stand to benefit most immediately, while pure-play recreational companies face continued uncertainty. State programs must maintain compliance with existing medical marijuana frameworks to qualify for the new classification.

Market dynamics shift considerably as institutional investors gain clearer regulatory footing to evaluate cannabis investments. The reclassification removes some compliance barriers for banks and payment processors serving state-licensed medical operators, though comprehensive banking reform requires separate congressional action. Federal agencies now must develop implementation guidelines that balance state program autonomy with federal oversight requirements.